Clinical trials: Glioblastoma, Adult
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme
This randomized phase II trial is studying how well neoadjuvant and adjuvant fenretinide works compared to adjuvant fenretinide alone in treating patients who are undergoing surgical resection for recurrent glioblastoma…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00075491
- Testing
- fenretinide, therapeutic conventional surgery, pharmacological study
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Brain Cancer, Glioblastoma Multiforme
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase I Objectives: -To determine the maximum tolerated dose (MTD) of vorinostat + erlotinib versus vorinostat + erlotinib + temozolomide in adult patients with recurrent glioblastoma multiforme (GBM) and anaplastic gliomas.
- Trial name
- NCT01110876
- Testing
- Vorinostat, Erlotinib, Temozolomide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
RATIONALE: Biological therapies, such as lymphokine-activated killer cells, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00814593
- Testing
- lymphokine-activated killer cells, polifeprosan 20 with carmustine implant
- Where
- United States
- Sponsor
- Lisata Therapeutics, Inc.
Brain and Central Nervous System Tumors
COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors
RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have progressive or recurrent brain tumors following…
- Trial name
- NCT00004147
- Testing
- incyclinide
- Where
- 9 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioblastoma, Brain Neoplasm
Bevacizumab With or Without Surgery for Adult Glioblastomas
Background: Glioblastoma (GBM) is the most common malignant brain tumor in adults. Patients with GBM are usually treated with surgery, radiation, and chemotherapy. Despite this treatment, most GBMs start growing again.
- Trial name
- NCT01413438
- Testing
- Craniotomy
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Brain and Central Nervous System Tumors
Brachytherapy in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Brachytherapy uses radioactive material to kill cancer cells remaining after surgery. PURPOSE: Phase I trial to study the effectiveness of brachytherapy in treating patients who have recurrent malignant glioma.
- Trial name
- NCT00045474
- Testing
- adjuvant therapy, iodine I 125
- Where
- 9 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.
- Trial name
- ASPIRE (NCT06389591)
- Testing
- pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Brain and Central Nervous System Tumors
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients…
- Trial name
- NCT00068770
- Testing
- radiation therapy, Celecoxib
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
End of Life, Cancer
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
- Trial name
- NCT05297734
- Testing
- Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care
- Where
- 17 sites in United States
- Volunteers
- 2,996 people
- Sponsor
- Stanford University
Glioblastoma Multiforme, Glioblastoma Multiforme, Adult
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
This phase II trial studies the effect of P140K MGMT hematopoietic stem cells, O6-benzylguanine, temozolomide, and carmustine in treating participants with supratentorial glioblastoma or gliosarcoma who have recently had surgery…
- Conditions
- Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
- Trial name
- hSTAR GBM (NCT05052957)
- Testing
- P140K-MGMT, O6-benzylguanine, Photon Based Radiotherapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Leland Metheny
Brain and Central Nervous System Tumors
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking some of the blood flow to the tumor.
- Trial name
- NCT00553150
- Testing
- everolimus, temozolomide, radiation
- Where
- 178 sites in United States
- Volunteers
- 122 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
This phase II trial studies how well dasatinib works in treating patients with glioblastoma multiforme or gliosarcoma that has come back.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00423735
- Testing
- Dasatinib, Pharmacological Study
- Where
- 188 sites in United States, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Glioma, Malignant
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Pear Bio has developed a 3D microtumor assay and computer vision pipeline through which the response of an individual patient's tumor to different anti-cancer regimens can be tested simultaneously ex vivo.
- Conditions
- Brain Tumor, Glioma, Malignant, Ependymoma, Oligodendroglioma
- Trial name
- PEAR-GLIO (NCT06038760)
- Testing
- Resection
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Ourotech, Inc.
Glioblastoma Multiforme
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
This trial is divided into two parts, a dose-escalation study (phase 1) and a randomized study (phase 2). The purpose of the dose-escalation study (phase 1) is to determine the safety, maximum tolerated dose (MTD), and efficacy…
- Trial name
- NCT01933815
- Testing
- TPI 287, Bevacizumab
- Where
- 9 sites in United States
- Volunteers
- 92 people
- Sponsor
- Cortice Biosciences, Inc.
Brain and Central Nervous System Tumors
Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00897663
- Testing
- gene expression analysis, microarray analysis, protein expression analysis
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Brain and Central Nervous System Tumors
Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT00492687
- Testing
- carboplatin, tamoxifen citrate, temozolomide
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
Glioblastoma
A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma
This is an open-label, two arm study. The trial will enroll a total of up to 36 patients. Arm A will enroll up to a total of 6 evaluable patients and Arm B will enroll up to a total of 30 evaluable patients.
- Trial name
- NCT04629209
- Testing
- ONC201
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
Glioblastoma Multiforme, Anaplastic Astrocytoma
AZD8055 for Adults With Recurrent Gliomas
Background: AZD8055 is an experimental cancer treatment drug that works by inhibiting a protein called mTOR, which is known to promote tumor cell and blood vessel growth and to control tumor s energy and nutrient levels.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Malignant Glioma
- Trial name
- NCT01316809
- Testing
- AZD8055
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Hematological Neoplasms, Non-Hodgkin's Lymphoma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension…
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT02223052
- Testing
- CC-486, Vidaza
- Where
- 10 sites in United States
- Volunteers
- 89 people
- Sponsor
- Celgene
Brain and Central Nervous System Tumors
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for some types of brain tumors.
- Trial name
- NCT00004017
- Testing
- conventional surgery, iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Peregrine Pharmaceuticals